| scholarly article | Q13442814 |
| P356 | DOI | 10.2174/156802608784936700 |
| P698 | PubMed publication ID | 18673166 |
| P2093 | author name string | Yifeng Xiong | |
| Bradley R Teegarden | |||
| Hussien Al Shamma | |||
| P433 | issue | 11 | |
| P921 | main subject | insomnia | Q1869874 |
| P304 | page(s) | 969-976 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Current Topics in Medicinal Chemistry | Q2734725 |
| P1476 | title | 5-HT(2A) inverse-agonists for the treatment of insomnia | |
| P478 | volume | 8 |
| Q38081485 | 5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders |
| Q33720437 | Advances in the management of insomnia |
| Q35154278 | An update expert opinion on management and research strategies in Parkinson's disease psychosis |
| Q38271292 | Current Phase II investigational therapies for insomnia |
| Q49200036 | Development of a UPLC-MS/MS method for determination of pimavanserin tartrate in rat plasma: Application to a pharmacokinetic study |
| Q35111356 | Does effective management of sleep disorders reduce cancer-related fatigue? |
| Q37667017 | Does effective management of sleep disorders reduce depressive symptoms and the risk of depression? |
| Q38017272 | Drugs for insomnia |
| Q37587178 | Emerging drugs for insomnia: new frontiers for old and novel targets |
| Q37450164 | Managing insomnia: an overview of insomnia and pharmacologic treatment strategies in use and on the horizon |
| Q37761381 | Neurochemical aspects of sleep regulation with specific focus on slow-wave sleep. |
| Q37709565 | New approaches for the treatment of sleep disorders |
| Q37853032 | New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges |
| Q48351742 | Novel Bivalent 5-HT2A Receptor Antagonists Exhibit High Affinity and Potency in Vitro and Efficacy in Vivo. |
| Q42950782 | Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders |
| Q94958342 | Novel pharmacological treatments for generalized anxiety disorder: Pediatric considerations |
| Q37630864 | Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system |
| Q34369646 | Pimavanserin for the treatment of Parkinson's disease psychosis |
| Q30524246 | Reduced levels of serotonin 2A receptors underlie resistance of Egr3-deficient mice to locomotor suppression by clozapine. |
| Q37871396 | Sedative antidepressants and insomnia |
| Q38693445 | Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators. |
| Q37464848 | Serotonin 5-HT(2A) Receptor Function as a Contributing Factor to Both Neuropsychiatric and Cardiovascular Diseases |
| Q38600048 | Serotonin and brain function: a tale of two receptors |
| Q37864859 | Sleep and its disorders in translational medicine |
| Q37897942 | Sleep neurobiology from a clinical perspective |
| Q48219472 | Structure-based identification of aporphines with selective 5-HT(2A) receptor-binding activity |
| Q37125668 | Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model |
| Q35919946 | Sustained Enhancement of Lateral Inhibitory Circuit Maintains Cross Modal Cortical Reorganization |
| Q36236864 | Synthesis and evaluation of aporphine analogs containing C1 allyl isosteres at the h5-HT(2A) receptor |
| Q34129640 | Synthesis and in Vivo Evaluation of Phenethylpiperazine Amides: Selective 5-Hydroxytryptamine2A Receptor Antagonists for the Treatment of Insomnia |
| Q37780551 | The expanding role of H1 antihistamines: a patent survey of selective and dual activity compounds 2005-2010. |
Search more.